Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




某些类型肺癌可见致癌基因融合

By LabMedica International staff writers
Posted on 26 Nov 2013
肺腺癌(非小细胞肺癌的一种形式)的某些子集由产生致癌的“融合基因”的突变所引发。

美国达纳-法伯癌症研究所 (Boston, MA, USA)和科罗拉多大学癌症中心 (Denver, USA)的研究者们对 36 名肺腺癌患者的肿瘤样品进行了下一代 DNA 测序,这些肿瘤患者没有任何已知的致癌基因突变。研究者发现,取自两位不吸烟女性患者样品的 NTRK1(神经营养性酪氨酸激酶受体 1 型)区域已融合为常见的远端基因(1 位患者发生于 MPRIP 基因,1 位患者发生于 CD74 基因)。

结果发表于 2013 年 10 月 27 日网络版的 Nature Medicine 杂志,揭示三份样品 (3.3%) 显示出 NTRK1 基因融合证据。

“这些结果提示,少数百分比的肺腺癌患者——此前没能发现癌细胞基因异常的人群——肿瘤生长受涉及 NTRK1 融合的驱动,”特约作者,达纳-法伯癌症研究所医学副教授 Pasi A. More...
Jänne 博士声称。“由于肺癌是一种常见的癌症,即使是百分之几的比率也具有显著的意义,经换算可成为大量的患者数量。我们的研究结果表明,针对此子集的肺癌患者进行靶向治疗可能有效。”

Related Links:
达纳-法伯癌症研究所 
科罗拉多大学癌症中心


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.